Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

In a recent SEC filing, Rolph Timothy, Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), disclosed the sale of company shares valued at approximately $1.74 million. The ...

Akero Therapeutics announced promising results from the 96-week Phase 2b HARMONY trial of efruxifermin (EFX) for treating pre-cirrhotic metabolic dysfunction-associated steatohepatitis ...

Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical ...

About Akero Therapeutics. Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have been assigned an average recommendation of “Buy” from the nine ratings firms that are covering the company, Marketbeat ...

Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Provided by GlobeNewswire May 12, 2025, 11:00:00 AM.

Akero Therapeutics shares gained 117% in early trading on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse scarring of the organ without worsening ...

SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH.